Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 8.01, 9.01 · 8-K

bioAffinity Technologies, Inc.

BIAFNASDAQEQUITYCurrent

Other Events

Item 8.01. Other Events. On November 11, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing that a record number of CyPath ® Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test.…

Filed Nov 17, 2026Accepted Nov 17, 2026, 8:03 AM ESTCIK 1712762Accession 0001493152-26-052713
Share

Company context

bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.

Current securities

Recent company filings

  1. Results of Operations and Financial ConditionNov 6, 2026
  2. 10-Q filingNov 6, 2026
  3. 424B5 filingNov 3, 2026
  4. 424B5 filingNov 2, 2026
  5. Other EventsOct 29, 2026

Registered securities in this filing

bioAffinity Technologies, Inc. · 8-K · Filed 2026-11-17

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.007 per share

Symbol
BIAF
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: From2026-11-112026-11-11_custom_CommonStockParValue0.007PerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants to purchase Common Stock

Symbol
BIAFW
Exchange
NASDAQ
Classification
WARRANT
Status
Current
Filing context

Context: From2026-11-112026-11-11_custom_WarrantsToPurchaseCommonStockMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000149315226052713 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events. On November 11, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing that a record number of CyPath ® Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

Exhibit 99.1 bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test October testing volume equals approximately 45% of all tests performed in the previous quarter SAN ANTONIO, Texas - November 11, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease and topically delivered therapeutics for skin cancer, today announced that a record number of CyPath® Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test. The October results demonstrate continued growth in test utilization by both established and newly ordering physicians. In October 2026, 235 CyPath Lung tests were performed, representing a 29% increase compared with October 2025. October 2026 testing volume was equivalent to approximately 45% of the total number of tests performed in Q3 2026. “October’s testing volume reflects our efforts to expand the commercial reach of CyPath Lung,” said Maria Zannes, President and Chief Executive Officer of bioAffinity Technolo…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.